The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
MuellerBM, RomerdahlCA, GilliesSD, Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol.1990;144(4):1382–1386.
3.
BeroisN, OsinagaE.Glycobiology of neuroblastoma: Impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol.2014;114(4):1–13.
4.
SchulzG, ChereshDA, VarkiNM, Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res.1984;44(12 Pt 1):5914–5920.
5.
BarkerE, ReisfeldRA. A mechanism for neutrophilmediated lysis of human neuroblastoma cells. Cancer Res.1993;53(2):362–367.
6.
MujooK, ChereshDA, YangHM, Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res.1987;47(4):1098–1104.
7.
ModakS, CheungNK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest.2007;25(1):67–77.
8.
HankJA, RobinsonRR, SurfusJ, Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res.1990;50(17):5234–5239.
9.
DesaiAV, FoxE, SmithLM, Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol.2014;74(5):1047–1055.
10.
YuAL, GilmanAL, OzkaynakMF, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med.2010;363(14):1324–1334.
11.
OzykaynakMF, GilmanAL, YuAL, A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. J Clin Oncol.2014. Abstract 10044. http://meetinglibrary.asco.org/content/125658-144. Accessed July 20, 2015
12.
GilmanAL, OzkaynakMF, MatthayKK, Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol.2009;27(1):85–91.
13.
AlbertiniMR, GanJ, JaegerP, Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother Emphasis Tumor Immunol.1996;19(4):278–295.
14.
HandgretingerR, AndersonK, LangP, A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A(2):261–267.
15.
YuAL, Uttenreuther-FischerMM, HuangCS, Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol.1998;16(6):2169–2180.
16.
LibbyEN, BeckerPS, BurwickN, Panobinostat: A review of trial results and future prospects in multiple myeloma. Expert Rev Hematol.2015;8(1):9–18.
SavelievaM, WooMM, SchranHPopulation pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. Eur J Clin Pharmacol.2015;71(6):663–672.
19.
CliveS, WooMM, NydamT, Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol.2012;70(4):513–522.
20.
SharmaS, WitteveenPO, LolkemaMP, A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol.2015;75(1):87–95.
21.
San-MiguelJF, HungriaVT, YoonSS, Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol.2014;15(11):1195–1206.
22.
RichardsonPG, SchlossmanRL, AlsinaM, PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomibrefractory myeloma. Blood. 2013;122(14):2331–2337.
23.
San-MiguelJF, RichardsonPG, GüntherA, Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol.2013; 31(29):3696–3703.
24.
CassierPA, LefrancA, AmelaEYA phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013;109(4):909–914.
25.
BerdejaJG, HartLL, MaceJR, Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100(5):670–676.
26.
BerensonJR, HilgerJD, YellinOA phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol.2014;93(1):89–98.
27.
BauerS, HilgerRA, MühlenbergT, Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer. 2014;110(5):1155–1162.
28.
GrayJE, HauraE, ChiapporiA, A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res.2014;20(6):1644–1655.
29.
LeeEQ, ReardonDA, SchiffD, Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol.2015;17(6):862–867.
30.
MangiacavalliS, PochintestaL, RavelliE, Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. Leuk Lymphoma. 2015;56(6):1901–1902.
31.
OcioEM, DávilaJ, CaballeroJC, Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica. 2015;100(7):e289–291.
32.
OkiY, BuglioD, FanaleM, Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res.2013;19(24):6882–6890.
33.
TanP, WeiA, MithraprabhuS, Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J.2014;4(e170):1–8.
34.
TarhiniAA, ZahoorH, McLaughlinB, Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Res.2013;33(10):4475–4481.
